J.P. Morgan Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), ...
Royalty Pharma Reports Third Quarter 2024 Results
Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full ...
Pharmabiz6h
Ascendis Pharma, Novo Nordisk ink collaboration to develop & commercialize TransCon technology-based products in metabolic and cardiovascular diseases
Ascendis Pharma A/S announced that it has granted Novo Nordisk A/S an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary ...
pharmaphorum7h
Wegovy romps ahead after key rival sees slowdown
GLP-1 agonist Wegovy (semaglutide) brought in DKK 17.3 billion ($2.49 billion) in the period, restoring earlier levels of ...
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA
Ascendis Pharma will license its TransCon technology to Novo to develop therapies for metabolic and cardiovascular diseases.